Clinical Trials | March 03, 2026
AbbVie’s Risankizumab shows strong results in hard-to-treat Crohn’s disease patients
This study evaluated a difficult-to-treat Crohn's disease patient population
This study evaluated a difficult-to-treat Crohn's disease patient population
Our clinical data suggests ProLectin-M demonstrated earlier reductions in viral shedding compared with placebo with a favorable safety profile
Achondroplasia, a rare genetic disorder, causes skeletal dysplasia and often increases the risk of muscular, neurological, and cardiorespiratory complications
During live demonstrations, industry leaders highlighted SEOPRO’s ability to spot portfolio risk, execution bottlenecks, and decision delays early—before they escalate into costly program disruptions
VievePharm is renowned for its phytogenic formulations across livestock, equine, and pet care markets
The LIFT-PD study will enroll 75 Parkinson’s patients experiencing apathy across 16 sites in Germany, Bulgaria, Poland and Spain
The construction projects, which have already begun, will be finalised gradually from the end of 2027 through 202
Emcure to distribute Roche's kidney transplant and anemia drugs in India
Fenebrutinib has the potential to become the first and only high-efficacy oral, brain-penetrant treatment for both RMS and PPMS, showing a profound benefit on relapsing and progressive disease biology
The results, published in The Lancet, showed orforglipron delivered significantly greater reductions in both A1C and body weight across primary and key secondary endpoints
Subscribe To Our Newsletter & Stay Updated
